Best AIM stocks to buy in July

We asked our writers to share their best AIM-listed stocks to buy for July, including a 2020 Hidden Winners recommendation!

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Chalkboard representation of risk versus reward on a pair of scales

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

We asked our freelance writers to share their top ideas for stocks listed on the Alternative Investment Market (AIM) to buy with investors — here’s what they said for July!

[Just beginning your investing journey? Check out our guide on how to start investing in the UK.]

Bioventix

What it does: Bioventix develops and supplies high-affinity monoclonal antibodies for use in clinical diagnostics

By Paul Summers: AIM isn’t known for being overburdened with quality companies. However, one clear example is Bioventix (LSE: BVXP). 

This biotech firm consistently generates astonishing margins. In fact, Bioventix is arguably one of the best companies in the UK based on this metric.

Recent trading has been reassuringly solid too. Pre-tax profit jumped 27% to £4.5m in its last set of interim results.

Throw in a rock-solid balance sheet and an enviable position in its niche market and there’s a lot to like.

Unfortunately, the shares currently change hands for almost 26 times forecast earnings. That’s fairly rich even when investor sentiment is high, let alone during a period of economic strife.

This could prove problematic if, for whatever reason, the firm issues a less-than-encouraging update.

Then again, you tend to get what you pay for. I doubt Bioventix stock will ever be available for a bargain-basement price.

Paul Summers has no position in Bioventix.

Cerillion

What it does: Cerillion is a software business that provides billing, charging, and customer relationship management (CRM) solutions, predominantly to telecoms firms.

By Edward Sheldon, CFA. There are three main reasons I’ve selected Cerillion (LSE: CER) as my top AIM stock this month.

The first is that the company has a lot of momentum right now. For the six-month period to the end of March, it posted revenue of £20.5m, up 27% year on year, and adjusted earnings per share of 25.5p, up 37%.

The second is that the company just raised its interim dividend by a whopping 27% to 3.3p per share. This suggests to me that management is very confident about the future.

The third reason is that it has positive share price momentum. This is a stock that is in a very strong uptrend right now. I’d much rather buy a stock that is trending up than one that’s trending down.

Now, it’s worth noting that Cerillion does have a high valuation. Currently, the forward-looking P/E ratio here is in the low 30s. I’m comfortable with the valuation given the strong growth here. However, it does add some risk.

Edward Sheldon owns shares in Cerillion.

Creo Medical  

What it does: Creo Medical is a medial devices company that manufactures instruments used in endoscopic surgery.   

By Ben McPoland. Creo Medical (LSE: CREO) is an intriguing AIM stock. Its flagship Speedboat Inject product is a multimodal instrument designed for flexible endoscopy. Instead of being just a long, camera-mounted tube looking inside a patient’s body, this product is more like a high-tech Swiss army knife. It can dissect, cut out, inject and coagulate all in a single device.

This makes procedures far less invasive, potentially turning hospital stays into routine one-day visits. Indeed, Creo estimates that its Speedboat device saves the NHS £5,000 per procedure. More clinicians around the globe are now being trained on its suite of electrosurgical products.

Furthermore, its instruments are powered by an advanced – and patented – energy system. And it is already licensing its technology out to other firms, including robotics giant Intuitive Surgical

The company recently raised over £33m to fund its growth, and management expects this will be sufficient to reach positive cash flow by 2025.

Though there’s a risk that doesn’t happen, I’m backing Creo to become a much larger company.

Ben McPoland owns shares in Creo Medical and Intuitive Surgical.

Michelmersh Brick Holdings

What it does: Michelmersh is a premium brick manufacturer that owns brands including Blockleys, Carlton and Hathern Terra Cotta.

By Roland Head. My top AIM stock right now is Michelmersh Brick Holdings (LSE: MBH). Shares in this specialist firm have fallen by a third from their 2021 highs. I think they look excellent value on a medium-term view.

The main risk facing the business is that the housing slump will be more severe than expected, perhaps alongside a UK recession. A wider construction downturn could also be problematic.

Michelmersh’s valuation could become more depressed in this scenario. But I think the company’s portfolio of distinctive brands and £10m net cash balance mean that it will ride out any short-term headwinds and return to profitable growth.

I’m also reassured by the combined 28% shareholding of co-founders Eric Gadsden and Martin Warner, who remains chairman.

The stock currently trades on around nine time forecast earnings with a 4% dividend yield. If I didn’t already own shares in a housebuilder, I’d be buying at this level.

Roland Head does not own shares in Michelmersh Brick Holdings.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

The Motley Fool UK has recommended Bioventix Plc, Cerillion Plc, and Intuitive Surgical. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

7%+ dividend yields! Here are 2 of the best UK shares to consider buying in June

This Fool has been searching for UK shares with the best dividend yields. Here are two he thinks investors should…

Read more »

Investing Articles

5 FTSE 100 shares to consider buying for passive income right now

The FTSE 100 is having its best start to the year for ages, and that's pushing the top dividend yields…

Read more »

Investing Articles

One overlooked cheap share to tap into the year’s hottest theme?

This Fool describes the key things to think about when investing in copper stocks and analyses one cheap share to…

Read more »

Investing Articles

A cheap FTSE 100 stock that’s ready for a dividend hike in 2024

This banking giant is one of the FTSE 100's greatest dividend stocks. And at current prices, our writer Royston Wild…

Read more »

Growth Shares

Is the BP share price set to soar after Michael Burry invests in the firm?

Jon Smith takes note of a recent purchase from the famous investor behind The Big Short and explains his view…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

I’d focus on Kingfisher now after the Q1 report leaves the share price unmoved

With the share price near 262p, is the FTSE 100’s Kingfisher a decent investment now for dividends and business recovery?

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

£500 buys me 493 shares in this 7.4% yielding dividend stock!

The renewable energy sector remains out of favour. As a result, there are some high-yielders around, including this dividend stock.

Read more »

Road trip. Father and son travelling together by car
Investing Articles

If I’d put £10k into Tesla stock 2 years ago, here’s what I’d have now

Tesla stock has fallen in the past few years. But the valuation looks temptingly low now, as we approach a…

Read more »